OXiGENE Announces Clinical Data From FACT and FALCON Studies to be Presented at ASCO

by Allie Wickman, Benzinga Staff Writer
May 18, 2011 8:05 AM | 16 seconds read |
OXiGENE OXGN announced today that data from its clinical trials of ZYBRESTAT in combination with chemotherapy in patients with anaplastic thyroid cancer and non-small cell lung cancer will be presented at the upcoming American Society of Clinical Oncology annual meeting in Chicago, Illinois on June 3-7, 2011.
Market News and Data brought to you by Benzinga APIs

© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Comments
Posted In: NewsFDABiotechnologyHealth Care
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!